About
Neuralymed is a clinical stage biotechnology company developing disease-modifying therapies targeting neurodegenerative diseases such as Parkinson's and Alzheimer's by inhibiting pathological glial activation to prevent neuronal cell death.
Explore Neuralymed's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.